With Losses Mounting, This Marijuana Company Could Use a Win in 2016

GW Pharmaceuticals hopes that its big-time spending on medical marijuana research could finally prove worthwhile.

Marijuana drug developer GW Pharmaceuticals plc (NASDAQ:GWPH) is plowing tens of millions of dollars into marijuana research and development every quarter, but trial failures in cancer pain and schizophrenia last year are increasing worry that its efforts will prove futile.

This year, GW Pharmaceuticals expects to report data from a slate of trials evaluating its marijuana drug Epidiolex in epilepsy patients. Can these trials get the company back on track? Read on to find out what's at stake. 

First, a bit of background
A recent study from the Washington University School of Medicine estimates that the number of people who use marijuana grew 20% between 2002 and 2013 and that 12.5% of Americans use marijuana.

That finding isn't surprising given Americans' improving attitude toward marijuana. According to Gallup, 58% of Americans think marijuana...

Rate this article: 

This marijuana news is brought to you by 420 Intel. For the latest breaking cannabis industry news, subscribe to the 420 Intel newsletter. If you'd like to promote your product or service in this area after every article, contact us.